GIAPREZA is the first and only FDA-approved synthetic human angiotensin II that increases blood pressure in adults with septic or other distributive shock.

RAAS


WHY GIAPREZA?

Only GIAPREZA activates the RAAS system to increase MAP

Watch the GIAPREZA mechanism of action video

70%


INCREASED MAP

70% of patients treated with GIAPREZA achieved target MAP at Hour 3 versus 23% of patients treated with placeboa,b,c

5 minutes


RAPID RESPONSE

GIAPREZA rapidly increased MAP with a median response time of approximately 5 minutesc,d

Granted New Technology Add-on Payment (NTAP) status by CMS

Learn more

Abbreviations: MAP, mean arterial pressure; RAAS, renin-angiotensin-aldosterone system.

aTarget MAP defined as ≥75 mmHg or an increase from baseline of ≥10 mmHg without an increase in baseline vasopressor therapy.

bGIAPREZA and placebo were studied in conjunction with norepinephrine, epinephrine, dopamine, phenylephrine, and vasopressin.

cResults from the ATHOS-3 trial.

dResponse was defined as achievement of target MAP ≥75 mmHg or increase of ≥10 mmHg from baseline without an increase in baseline vasopressor therapy.